Biological Therapy in Patients with Inflammatory Bowel Intestinal
Article Sidebar
Main Article Content
Abstract
Inflammatory bowel disease encompasses two important diseases such as ulcerative colitis and Crohn's disease, which are multifactorial pathology disorders that affect the intestinal tract causing a serious deterioration in the quality of life of patients who suffer from them and can even lead to colorectal cancer. For its treatment there are different drugs such as 5-aminosalicylates, topical steroids, systemic steroids, immunomodulators and immunosuppressants. When this conventional therapy does not show favorable results for the patients, biological therapy is applied, which allows modifying the natural history of the disease. The objective of this review is to describe the most effective biological therapy applied to patients with inflammatory bowel disease. The database used for the search of the information presented was PubMed, searching for articles in the period from 2018 to 2023, with the bibliographic descriptors DeCS and MeSH as: inflammatory bowel disease, biological therapy, Crohn's disease, and ulcerative colitis, enhancing the search with the Boolean operator AND. In the 20 articles obtained, it is possible to describe the remission rate achieved in the different patients who consumed biologic drugs such as: Infliximab, Adalimumab, Golimumab, Vedolizumab, Ustekinumab and Tofacitinib, describing remissions in periods of 8 to 10 weeks and 6 to 12 months. It was concluded that these drugs are more effective than placebo and are an excellent option for patient’s refractory to conventional treatment, improving their quality of life.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Derechos de autor
Las obras que se publican en 593 Digital Publisher CEIT están sujetas a los siguientes términos:
1.1. 593 Digital Publisher CEIT, conserva los derechos patrimoniales (copyright) de las obras publicadas, favorece y permite la reutilización de las mismas bajo la licencia Licencia Creative Commons 4.0 de Reconocimiento-NoComercial-CompartirIgual 4.0, por lo cual se pueden copiar, usar, difundir, transmitir y exponer públicamente, siempre que:
1.1.a. Se cite la autoría y fuente original de su publicación (revista, editorial, URL).
1.1.b. No se usen para fines comerciales u onerosos.
1.1.c. Se mencione la existencia y especificaciones de esta licencia de uso.
Celso Andrés Torres-Rosales , Universidad Católica de Cuenca - Ecuador
http://orcid.org/0009-0000-3794-1080
Undergraduate student of the career of Medicine, Catholic University of Cuenca, advisor in research works. Speaker at workshops for work implementation
Manuel Rafael Aldás-Erazo , Universidad Católica de Cuenca - Ecuador
http://orcid.org/0000-0003-1229-490X
Gastroenterologist, endoscopist, advisor and director of degree works. Author of Manual de Medicina Interna Hospitalaria Tomo 3 y 4, Comorbidity and survival in patients with colonic adenocarcinoma treated with chemotherapy and Quimioterapia en adenocarcinoma de colon. Comparison between FOLFOX 4 vs. 5FU/LV schemes in clinical stages II and III.
References
Abreu, M. T., Rowbotham, D. S., Danese, S., Sandborn, W. J., Miao, Y., Zhang, H., Tikhonov, I., Panaccione, R., Hisamatsu, T., Scherl, E. J., Leong, R. W., Arasaradnam, R. P., Afif, W., Peyrin-Biroulet, L., Sands, B. E., & Marano, C. (2022). Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. Journal of Crohn’s & Colitis, 16(8), 1222-1234. https://doi.org/10.1093/ecco-jcc/jjac030
Acuña Quirós, Ma, M. D., Alonso Franch, M., Álvarez Coca, J., Argüelles Martín, F., Armas Ramos, H., Barrio Merino, A., Barrio Torres, J., Bautista Casasnovas, A., Bedate Calderón, P., Berbel Tornero, O., & Blasco Alonso, J. (s. f.). PROTOCOLOS DIAGNÓSTICOS-TERAPÉUTICOS DE GASTROENTEROLOGÍA, HEPATOLOGÍA Y NUTRICIÓN PEDIÁTRICA SEGHNP-AEP. Recuperado 22 de abril de 2023, de https://www.seghnp.org/sites/default/files/2017-05/Protocolos%20SEGHNP.pdf
Barberio, B., Black, C. J., Savarino, E. V., & Ford, A. C. (2020). Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Journal of Crohn’s and Colitis. https://eprints.whiterose.ac.uk/168049/
Ben-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J., Kobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J. F., Kaplan, G. G., & Chen, M. (2022). Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology, 162(2), 482-494. https://doi.org/10.1053/j.gastro.2021.10.037
Danese, S., Sands, B. E., Abreu, M. T., O’Brien, C. D., Bravatà, I., Nazar, M., Miao, Y., Wang, Y., Rowbotham, D., Leong, R. W. L., Arasaradnam, R. P., Afif, W., & Marano, C. (2022). Early Symptomatic Improvement After Ustekinumab Therapy in Patients with Ulcerative Colitis: 16-Week Data from the UNIFI Trial. Clinical Gastroenterology and Hepatology, 20(12), 2858-2867.e5. https://doi.org/10.1016/j.cgh.2022.02.050
Flynn, S., & Eisenstein, S. (2019). Inflammatory Bowel Disease Presentation and Diagnosis. Surgical Clinics of North America, 99(6), 1051-1062. https://doi.org/10.1016/j.suc.2019.08.001
Gompertz, M., & Sedano, R. (2019). Manifestaciones clínicas y endoscópicas en enfermedad inflamatoria intestinal. Revista Médica Clínica Las Condes, 30(4), 273-282. https://doi.org/10.1016/j.rmclc.2019.06.002
Guan, Q. (2019). A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019, 7247238. https://doi.org/10.1155/2019/7247238
Kucharzik, T., Koletzko, S., Kannengiesser, K., & Dignass, A. (2020). Ulcerative Colitis—Diagnostic and Therapeutic Algorithms. Deutsches Ärzteblatt International, 117(33-34), 564-574. https://doi.org/10.3238/arztebl.2020.0564
Mayorga Garcés, A., Rodríguez Vélez, V., Dávila Bedoya, S., Andrade Zamora, D., Carrillo Ubidia, J., & Ordoñez Arce, M. (2020). Epidemiología y comportamiento de la enfermedad inflamatoria intestinal en la población ecuatoriana. Acta gastroenterológica latinoamericana, 50(1). https://doi.org/10.52787/SMTI9811
Morales, S. S. F., & Orrego, A. M. G. (2021). Guía diagnóstica y terapéutica de la enfermedad inflamatoria intestinal. Revista Medica Sinergia, 6(9), Article 9. https://doi.org/10.31434/rms.v6i9.713
Pantavou, K., Yiallourou, A. I., Piovani, D., Evripidou, D., Danese, S., Peyrin-Biroulet, L., Bonovas, S., & Nikolopoulos, G. K. (2019). Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterology Journal, 7(10), 1285-1303. https://doi.org/10.1177/2050640619883566
Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., Lees, C., Louis, E., Lukáš, M., Reinisch, W., Roblin, X., Jang, M., Byun, H. G., Kim, D.-H., Lee, S. J., & Atreya, R. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterology, 22, 291. https://doi.org/10.1186/s12876-022-02347-1
Seyedian, S. S., Nokhostin, F., & Malamir, M. D. (2019). A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life, 12(2), 113-122. https://doi.org/10.25122/jml-2018-0075
Sulz, M. C., Burri, E., Michetti, P., Rogler, G., Peyrin-Biroulet, L., Seibold, F., & on behalf of the Swiss IBDnet, an official working group of the S. S. of G. (2020). Treatment Algorithms for Crohn’s Disease. Digestion, 101(Suppl. 1), 43-57. https://doi.org/10.1159/000506364
Syversen, S. W., Goll, G. L., Jørgensen, K. K., Sandanger, Ø., Sexton, J., Olsen, I. C., Gehin, J. E., Warren, D. J., Brun, M. K., Klaasen, R. A., Karlsen, L. N., Noraberg, G., Zettel, C., Ljoså, M. K. A., Haugen, A. J., Njålla, R. J., Bruun, T. J., Seeberg, K. A., Michelsen, B., … Haavardsholm, E. A. (2021). Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients with Chronic Immune-Mediated Inflammatory Diseases. JAMA, 325(17), 1744-1754. https://doi.org/10.1001/jama.2021.4172
Wright, E. K., Ding, N. S., & Niewiadomski, O. (2018). Management of inflammatory bowel disease. The Medical Journal of Australia, 209(7), 318-323. https://doi.org/10.5694/mja17.01001
Yamamoto-Furusho, J. K., Bosques-Padilla, F. J., & Martínez-Vázquez, M. A. (2021). Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista de Gastroenterología de México, 86(1), 70-85. https://doi.org/10.1016/j.rgmx.2020.10.001
Yin, J., Li, Y., Chen, Y., Wang, C., & Song, X. (2022). Adalimumab for induction of remission in patients with Crohn’s disease: A systematic review and meta-analysis. European Journal of Medical Research, 27, 190. https://doi.org/10.1186/s40001-022-00817-6
Zaltman, C., Amarante, H., Machado, M. B., Costa, M. H. M., Flores, C., Leal, R. F., Genoile, S., & Zeroncio, M. (2019). Crohn’s disease—Treatment with biological medication. Revista Da Associação Médica Brasileira, 65, 554-567. https://doi.org/10.1590/1806-9282.65.4.554